{"entity":{"id":"nct07269626","kind":"trial","name":"PULSAR in Systemic Therapy for Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial in pancreatic cancer, run by Samsung Medical Center, now recruiting.","summary":"PULSAR in Systemic Therapy for Pancreatic Cancer is a phase 2, interventional study registered as NCT07269626 by Samsung Medical Center, with a registry enrolment figure of 47 participants, started 2025-11-14 and due to reach its primary completion in 2027-12-31. Interventions recorded: Personalized Ultrafractionated Adaptive Radiotherapy. Conditions listed: Locally Advanced Pancreatic Ductal Adenocarcinoma; Borderline Resectable Pancreatic Ductal Adenocarcinoma; Oligometastatic Pancreatic Ductal Adenocarcinoma. Primary outcome: progression-free survival at 1-year after enrollment; Progression-free survival; Local control (LC). Pancreatic eligibility wording from the registry: \"* Histologically confirmed pancreatic ductal adenocarcinoma\". Sites: South Korea. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07269626","url":"https://clinicaltrials.gov/study/NCT07269626"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["borderline-resectable-pdac","resectable-pdac","locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07269626","phase":"2","setting":"A Prospective Phase II Study of Systemic Therapy With Combined Personalized Ultrafractionated Stereotactic Adaptive Radiation Therapy (PULSAR) in Pancreatic Cancer","sponsor":"Samsung Medical Center","enrolled":47,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07269626/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}